WEE1 and B-cell chronic lymphocytic leukemia: Two of them, the PI3Kδ inhibitor Idelalisib and the BTK inhibitor Ibrutinib, have demonstrated good efficacy with tolerable doses, and have been recently approved by the FDA for their use in relapsed or refractory CLL [13,14], providing evidence that downregulation of protein kinases important for tumor cell survival can be a useful strategy for the treatment of CLL.